Global Meningococcal Vaccines Market Size to grow USD 5.07 Billion by 2030 | CAGR of 6.5%

Global Meningococcal Vaccines Market worth $5.07 billion by 2030

According to a research report published by Spherical Insights & Consulting, the Global Meningococcal Vaccines Market size to grow from USD 2.88 billion in 2021 to USD 5.07 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period.  The meningococcal vaccine market has grown due to the increasing prevalence of meningitis disease. In addition, growing awareness about the disease, increasing R&D, and rising immunization programs are helping in market growth.

Browse key industry insights spread across 208  pages with 139  market data tables and figures & charts from the report "Global Meningococcal vaccines market Size, Share, and COVID-19 Impact Analysis, By Type (Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, and Others), By Brand Name ( Menactra, Menveo, Nimenrix, Trumenba, Bexsero, and Others), By End-user (Hospitals, Pharmacy Stores, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Analysis and Forecast 2021 – 2030.", in detail along with the table of contents. https://www.sphericalinsights.com/reports/meningococcal-vaccines-market

View a detailed Table of Content here– https://www.sphericalinsights.com/table-of-contents/meningococcal-vaccines-market

The COVID-19 pandemic has made an adverse impact on credit portfolios. There has been an unprecedented rise in unemployment and disruption in economic activity, putting a strain on the solvency of customers and companies. Central banks have taken a proactive approach by injecting liquidity into the market by lowering interest rates and asset purchase programs. Managing and monitoring credit, market, liquidity, and operational risk across financial markets were hard enough with ongoing geopolitical tensions, international trade wars, and the occasional hurricanes and earthquakes. The current pandemic situation has forced chief risk officers and their teams to recalibrate old assumptions and models used to manage and monitor risk. COVID-19’s global impact has shown that interconnectedness plays an important role in international cooperation. As a result, many governments started rushing toward identifying, evaluating, and procuring reliable solutions powered by AI.

The polysaccharide vaccines segment accounts for the largest market size during the forecast period

Based on the type, the global meningococcal vaccines market is categorized into Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, and Others. The polysaccharide vaccines segment accounts for the largest market size during the forecast period.  Due to the limited supply from a few vaccine makers, developing countries are still very interested in polysaccharide vaccines. The leaders in the market are working with local distributors to reach more people. Research that will be published by the National Institute of Health in 2021 shows that people with diabetes have twice the chance of getting meningitis. Diabetes is one of the most important risk factors because it makes it much more likely that a person will get meningitis.

The bexsero segment to hold a higher CAGR during the forecast period

Based on a brand name, the meningococcal vaccines market is categorized into Menactra, Menveo, Nimenrix, Trumenba, Bexsero, and Others. The bexsero segment to hold a higher CAGR during the forecast period. Bexsero is approved for use in more than 40 countries, including New Zealand, Argentina, Chile, Australia, Israel, Uruguay, Turkey, and Europe. The high rate of acceptance of the vaccine that protects against meningococcal infections caused by serotype B can also be linked to the growth in market share.

The hospital segment to hold a higher CAGR during the forecast period

Based on end-user, the meningococcal vaccines market is categorized into Hospitals, Pharmacy Stores, and Others. The hospital segment to hold a higher CAGR during the forecast period. The hospital segment is rising with the increase in awareness among people regarding meningococcal vaccines.

North America is estimated to account for the highest market share in 2021.

The Global meningococcal vaccines market has been segmented into five major regions: Asia-Pacific, Europe, APAC, Latin America, and MEA. There are a lot of things that are driving the market in North America. Some of them are good government recommendations and support and strong spending on research and development. A well-developed healthcare system and an increase in the number of awareness campaigns in the region are also expected to help the market grow. People at the market also participate in a campaign to raise awareness about meningococcal disease and get more people vaccinated. For example, in August 2021, GlaxoSmithKline Plc started a campaign called ASK2BSure to get parents to take their kids to the paediatrician to get the meningitis B vaccine. Asia-Pacific to hold a higher CAGR during the forecast period.

Major vendors in the global meningococcal vaccines market include Bio-Manguinhos, Biomed Pvt. Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Pasteur Inc., and Serum Institute of India Ltd.

Related Report:

Global TCV Vaccines Market Size, Share, Forecast 2030

https://www.sphericalinsights.com/reports/tcv-vaccines-market

Global Yellow Fever Treatment Market Size, Share, Forecast 2030

https://www.sphericalinsights.com/reports/yellow-fever-treatment-market

Contact Us: https://www.sphericalinsights.com/contact-us